Skip to main content
. 2016 Dec 2;2016(1):24–32. doi: 10.1182/asheducation-2016.1.24

Figure 4.

Figure 4.

Algorithm for the treatment of t-MN patients. *None of the mentioned treatments are currently approved for AML. alloHCT, allogeneic hematopoietic stem cell transplantation; CAR, chimeric antigen receptor; CBF, core-binding factor leukemia (ie, AML with t(8;21), inv(16), or t(16;16)); CR1, first complete remission; DA, daunorubicine and cytarabine; ITD, internal tandem duplication.